Fig. 1From: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicityScreening of potent PD-L1 binders through OmniMab phagemid library. A Top four high-affinity binders that bind to PD-L1. The binding affinity of four PD-L1 antibody candidates to recombinant PD-L1 was determined using ELISA. B PD-1/PD-L1 blocking assay of the top four PD-L1 antibody candidates. Competitive binding of PD-1/PD-L1 was analyzed by ELISA. C The top four PD-L1 antibody candidates were analyzed for their ability to enhance CD4 + T cell activation in the allogeneic MLR. The secretion of IL-2 and IFN-γ in the culture supernatant was measured by ELISA. Clone #6 showed the better dose-dependent bioactivity in promoting the secretion of cytokine IL-2 and IFN-γBack to article page